Navigation Links
Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
Date:12/9/2008

Data Support Case for DNA-Guided Medicine in Psychiatry

HARTFORD, Conn., Dec. 9 /PRNewswire/ -- Results from a clinical study published in the current issue of the Future Medicine Group (London) journal Personalized Medicine (Vol. 5, No. 6, pp. 579-587, 2008) are helping to point the way toward the application of DNA-guided medicine to predict psychotropic side effects. The study was conducted at The Institute of Living of Hartford Hospital in collaboration with Genomas.

The CYP2C9, CYP2C19 and CYP2D6 genes from the cytochrome P450 family were chosen for DNA typing because their common variants result in deficient metabolic capacity for many psychotropic drugs. Combinatorial gene analysis revealed that 57 percent of individuals in the psychiatric population were carriers of multiple gene variations associated with no or poor drug metabolism capacity on 2 or 3 genes compared to 36 percent of individuals in the control population. Individuals that are multiply deficient in CYP450 metabolic routes are at risk for developing serious side effects to a variety of psychotropic medications.

"We found clear evidence that there were significantly more innate drug metabolism deficiencies based on the gene variants predominantly observed in the population experiencing side effects," said Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, and Director of Genetics Research, Hartford Hospital. "Our goal is to enhance patient safety by preventing predictable side effects and at the same time build the case for DNA typing in the optimized utilization of health care resources. We are integrating this clinical experience with development of our PhyzioType Systems for DNA-Guided Medicine."

ABOUT GENOMAS

Genomas(R) Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. www.genomas.net


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA Training ... Institute Education Center headquartered in Northern California, has issued an important reminder to ... their worksites. Employers with workers exposed to high temperatures should establish a ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):